Worksport Sees Record Growth in FY 2025, Sets Stage for Transformative Year Ahead

Worksport Sees Record Growth in FY 2025, Sets Stage for Transformative Year Ahead


On a recent conference call, Worksport CEO Steven Rossi delivered exciting news about the company's Fiscal Year (FY) 2025 performance. The company's Q4 2025 earnings call revealed significant milestones, including nearly doubling its full-year net sales to $616.1 million and achieving a gross margin improvement of 2,800 basis points from 11% in 2024.

"2025 was a year of real top-line growth and significant margin improvement," Rossi stated during the call. "Our fiscal 2025 strategies to expand our presence in multiple sales channels, introduce new products, and increase our market capture resulted in a net operating loss and increased use of our cash otherwise generated from our growing operations."

The company's focus on expanding its product offerings and increasing its presence in both Direct-To-Consumer and Business-To-Business (B2B) sales channels played a significant role in its success. Worksport's product capitalization to market delivery, brand and sales channel distribution presence, both with DTC and B2B customers, have been key drivers of growth.

Worksport's Chief Financial Officer, Michael Johnston, noted the company's ability to generate positive operating cash flows is a top priority for the next phase of growth. The company has learned valuable lessons from navigating entry and growth in different sales channels, which will inform its strategy moving forward.

The company's prepared remarks and presentation deck will be available for download at www.worksport.com following the call. In his comments, Rossi emphasized that while 2025 was a transformative year, there is still work ahead. The company has set the stage for a remarkable year in FY 2026 with its keen focus on lean operations and generating positive operating cash flows.

With its strong foundation in place, Worksport is poised to capitalize on new opportunities, expand its product offerings, and increase its market presence. As the company looks ahead to FY 2026, it is clear that this year will be transformative for Worksport, with significant milestones expected across multiple product lines.

Read more

Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

In a groundbreaking fourth quarter earnings call, Bicara Therapeutics unveiled an array of remarkable achievements that catapulted the clinical-stage biotech company to unprecedented heights. Under the leadership of CEO Claire Mazumdar, the company has been diligently pioneering bifunctional antibodies for targeted tumor modulation. Their innovative approach combines tumor targeting with

By Julia Horowitz